Synthesis and Evaluation of N-(3-Trifluoroacetyl-indol-7-yl) Acetamides for Potential In Vitro Antiplasmodial Properties

Abstract

A series of novel N-((2,5-diaryl-3-trifluoroacetyl)-1H-indol-7-yl)acetamides has been prepared via a successive and one-pot reaction sequence involving initial trifluoroacetic acid-mediated Beckmann rearrangement of the oximes derived from the 1-(2,5-diaryl-1H-indol-7-yl)ethanones, followed by trifluoroacetylation of the incipient N-(2,5-diaryl-1H-indol-7-yl)-acetamides with trifluoroacetic anhydride. The prepared compounds were evaluated for potential in vitro antiplasmodial properties. Preliminary results from antiplasmodial activity against the chloroquine-sensitive 3D7 strain of Plasmodium falciparum revealed that a combination of 2-(4-flurophenyl)- and 5-(4-fluorophenyl) or 2-(4-flurophenyl)- and 4-fluorostyryl groups in compounds 3(a,f) and 4(a,g), for example, is required for biological activity for both series of compounds. Their possible mode of action against the plasmodial parasite is explained theoretically through molecular docking of the most active compounds against the parasite lactate dehydrogenase (pLDH). These compounds were docked at the entrance of NAD+ in pLDH presumably hindering entry of lactate to cause the observed inhibition effect of pLDH. The four compounds were found to exhibit low toxicity against monkey kidney Vero cells at the highest concentrations tested.

1. Introduction

There has been growing interest in the development of efficient methods that allow for rapid access to functionalized indoles with different substitution pattern on the heterocyclic and aromatic rings due to their diverse biological properties, which include antimicrobial, antimalarial, anti-oxidant, anticancer and antitubercular activities [1,2,3]. The 7-aminoindole moiety constitutes an important scaffold for the development of compounds with antimalarial and anti-oxidant activities [3,4,5,6,7] and some of the compounds serve as anion receptors especially for dihydrogen phosphate [8]. Melatonin (A), which is shown in Figure 1, is an example of a carboxamide-appended indole derivative which plays a central role in the control of Plasmodium falciparum replication and establishment of parasitemia [9]. The presence of a hydrogen-bond acceptor at the C-3 position of an indole moiety such as carbonyl group is important for interaction with the biological receptors [10].

In a previous study we evaluated some 1-(2,5-diarylindol-7-yl)ethanones for in vitro cytotoxicity against the human breast adenocarcinoma (MCF-7) and human cervical cancer (HeLa) cell lines [11]. In an effort to synthesize new compounds with antimalarial potential, we decided to transform the 1-(2,5-diarylindol-7-yl)ethanones into analogues of melatonin. Our strategy towards the indole-appended acetamides involved the Beckmann rearrangement of oximes derived from the 1-(2,5-diarylindol-7-yl)ethanones to afford the N-(indol-7-yl)acetamides. The latter were, in turn, transformed via C-3 trifluoroacetylation to afford the corresponding N-(2,5-diaryl-3-trifluoro-acetylindol-7-yl)acetamides. The prepared N-(indol-7-yl)acetamides and their 3-trifluoroacetyl derivatives were evaluated for potential in vitro antiplasmodial properties against the chloroquine-sensitive 3D7 strain of Plasmodium falciparum to correlate structural variations to biological activity. The possible mode of action of these compounds against the plasmodium parasite is explained theoretically through molecular docking of the most active compounds against the parasite lactate dehydrogenase (pLDH).

2. Results and Discussion

2.1. Chemistry

In order to prepare the N-(2,5-diarylindol-7-yl)acetamides, we required the oxime derivatives of compounds 1 for participation in the Beckmann rearrangement. We reacted the known 1-(2,5-diarylindol-7-yl)ethanones 1a–g [11] with hydroxylamine hydrochloride in the presence of pyridine in ethanol under reflux and isolated the corresponding oximes 2a–g by column chromatography on silica gel (Scheme 1). The oxime derivatives were characterised using a combination of NMR (¹H and ¹³C) and IR spectroscopic techniques, complemented with mass spectrometry. Attempted Beckmann rearrangement of the keto-oximes 2 using molecular iodine in anhydrous acetonitrile [12] or triphenylphosphine-iodine catalyst complex in acetonitrile under reflux [13], led to the recovery of the starting material in both cases. We then decided to make use of a strong acid to promote the Beckmann rearrangement of compounds 2. In this case we opted for the low boiling and water miscible trifluoroacetic acid (TFA) which has been used extensively in organic synthesis to promote other types of rearrangement reactions, functional group deprotections, oxidations, reductions, condensations, hydroarylations and trifluoromethylations [14]. TFA in aprotic solvents was previously found to promote the Beckmann rearrangement of keto-oximes into amides or lactams [15]. Based on this literature precedent, we subjected the oxime derivatives 2a–g to TFA in acetonitrile under reflux for 2 h (Scheme 1). After aqueous workup and purification by silica gel column chromatography, we isolated compounds characterised using a combination of spectroscopic techniques as the desired novel N-(2,5-diarylindol-7-yl) acetamides 3a–g. The proton NMR spectra of these amide derivatives revealed the presence of a singlet at about δ 9.70 ppm corresponding to NH of the amide group. Formation of these compounds through aryl migration, on the other hand, was confirmed by a significant up-field shift of the methyl protons to around δ 2.19 ppm compared to those in the ¹H-NMR spectra of 1 (around δ 2.79 ppm) and 2 (around δ 2.38 ppm). Moreover, their carbonyl carbon resonates significantly up-field (δ_C=O 170 ppm) than that of the corresponding precursors 1 (δ_C=O 200 ppm) and more downfield than substrates 2 (δ_C=N 155 ppm). The methodology described in this investigation for the synthesis of C-7 aminated NH-free indoles is complementary to the method developed by Cacchi et al. [16], which makes use of the Buchwald-Hartwig C–N bond formation of the incipient 7-bromoindoles with primary and secondary amines. Series of 2,5- and 3,5-disubstituted 7-aminoindoles have also been prepared before via a three component Wittig reaction of pyrrole-3-carboxaldehydes with fumaronitrile and PEt₃ followed by chemoselective C-6 alkylation of the incipient cis-allylic nitriles and subsequent cyclization through an intramolecular Houben−Hoesch reaction [17].

Since the presence of a hydrogen-bond acceptor at the C-3 position of an indole moiety such as carbonyl group is important for interaction with the biological receptors [10], we decided to incorporate a trifluoroacetyl group at the 3-position of the ambident nucleophilic indole framework of the N-(2,5-diarylindol-7-yl)acetamides 3a–g to evaluate the resultant products for potential biological activity. We employed the literature conditions [18] on compounds 3a–g and subjected them to TFAA (1.5 equiv.) in THF under reflux for 5 h (Scheme 2). Aqueous work-up and column chromatography on silica gel afforded the corresponding N-(3-trifluoroacetylindol-7-yl)acetamides 4a–g in appreciable yields without traces of the N-substituted products. Incorporation of the trifluoroacetyl group was confirmed by the absence of a singlet for 3-H in the region δ 6.77–6.92 ppm found in the ¹H-NMR spectra of the corresponding substrates and the presence of two set of quartets at around δ 116.0 ppm and δ 176 ppm in the ¹³C-NMR spectra of 4, which correspond to the trifluoromethyl and carbonyl carbon signals, respectively. The presence of trifluoroacetyl group in compounds 4 was further confirmed by an intense peak at around δ −71.0 ppm in their ¹⁹F-NMR corresponding to -CF₃ in analogy with the literature precedents for the analogous 3-trifluoroacetylindoles [19]. We explored the possibility to effect sequential Beckmann rearrangement and C-3 trifluoroacetylation of the oximes 2a–g to afford compounds 4 in a one-pot operation. In this case, we subjected the oxime derivatives 2a–g to TFA (1.2 equiv.) in acetonitrile under reflux for 2 h followed by addition of TFAA (2 equiv.) and further heating under reflux for additional 5 h. We isolated by column chromatography on silica gel compounds 4a–g in high yield. Attempted one-pot sequential trifluoroacetylation of 2a–g with TFAA in THF or acetonitrile under reflux followed by Beckmann rearrangement, on the other hand, led to incomplete conversion of the incipient 3-trifluoroacetyl–substituted oximes after 12 h with traces of the 3-trifluoroacetylindoleacetamides detected in the crude mixture by thin layer chromatography and ¹H-NMR spectroscopy. We were also able to obtain single crystals of 4g suitable for X-ray diffraction studies by slow evaporation of a DMSO solution [20]. Crystal data and structure refinement, bond lengths and torsion angles are enclosed as part of the Supplementary Material. The crystal studied was an inversion twin (Figure 2). Thus, X-ray crystallography provided an unambiguous retrospective proof that the Beckmann rearrangement of the oximes derivatives 2 occurred via aryl migration.

As a guide to 7-aminoindoles with potential biological properties, we decided to evaluate compounds 3a–g and 4a–g for in vitro antiplasmodial activity against the chloroquine-sensitive strain of malaria parasite P. falciparum (3D7).

2.2. Biology

2.2.1. Antimalarial Activity Assay

The P. falciparum lactate dehydrogenase enzyme (pLDH) is considered as a potential molecular target for antimalarial agents due to this parasite’s dependence on glycolysis for energy production. The in vitro antiplasmodial activity of compounds 3a–g and 4a–g was measured by parasite survival using parasite lactate dehydrogenase (pLDH) assay with 100% DMSO and chloroquine as the negative and positive controls, respectively. Lactate dehydrogenase is an enzyme found in all cells that catalyzes the formation of pyruvate from lactate reducing the co-enzyme nicotinamide adenine dinucleotide (NAD) to NADH. In parasites, the NAD analogue 3-acetylpyridine adenine nucleotide (APAD) is reduced to APADH. In contrast, human red blood cell LDH carries out this reaction at a slow rate in the presence of APAD. The development of APADH is measured, and there is a correlation between levels of parasitemia and the activity of parasite LDH [21]. The IC₅₀ values are expressed as the % parasite survival relative to the control, calculated from fitted sigmoidal dose-response curves and are represented in

Table 1. IC₅₀ values of 3a–g and 4a–g and chloroquine against 3D7 strain of P. falciparum.

Compound	Ar1	Ar2	IC50 (μM)	SI
3a	4-FC6H4-	4-FC6H4-	1.43 ± 0.21	0.13
3b	4-MeOC6H4-	4-FC6H4-	6.34 ± 2.26	0.58
3c	4-FC6H4-	4-MeOC6H4-	6.33 ± 2.25	0.19
3d	4-MeOC6H4-	4-MeOC6H4-	11.01 ± 2.19	ND a
3e	C6H5-	4-FC6H4CH=CH-	5.19 ± 1.58	0.16
3f	4-FC6H4-	4-FC6H4CH=CH-	2.14 ± 0.52	0.20
3g	4-MeOC6H4-	4-FC6H4CH=CH-	14.03 ± 2.57	0.42
4a	4-FC6H4-	4-FC6H4-	2.52 ± 0.91	0.23
4b	4-MeOC6H4-	4-FC6H4-	5.21 ± 1.56	0.48
4c	4-FC6H4-	4-MeOC6H4-	6.15 ± 2.53	0.56
4d	4-MeOC6H4-	4-MeOC6H4-	9.31 ± 0.97	0.28
4e	C6H5-	4-FC6H4CH=CH-	7.25 ± 1.34	0.66
4f	4-FC6H4-	4-FC6H4CH=CH-	5.15 ± 1.63	0.47
4g	4-MeOC6H4-	4-FC6H4CH=CH-	3.39 ± 0.86	0.31
Chloroquine			0.01 ± 2.59

^a Not determined.

(refer to the supporting information for detailed data).

The selectivity index (SI) was calculated as the ratio of IC₅₀ values to the minimal inhibitory concentration (MIC) values and the compound is considered selective if the selectivity index is >10 [22]. The concentration of DMSO from 100 µM–5.13 × 10⁻³ µM had no effect on the parasites (91–109% parasite survival). The antiplasmodial activity of these novel compounds is between 1400 and 14,000 nM, which is very low compared to chloroquine activity (10 nM) and they have low selectivity index which ranges between 0.13–0.66. The MICs for compounds 3a, 3b, 3f, 4a–c and 4e–g was 11 µM while those for 3c, 3e, 3g and 4d was found to be 33 µM and 3d was found to have MIC of >100 µM. Nevertheless, some of the test compounds 3a–g and 4a–g were found to exhibit moderate to significant antiplasmodial activity against the chloroquine-sensitive strain of P. falciparum (3D7). Within series of the 3-unsubstituted N-(indol-7-yl)acetamides 3a–g, for example, the 2-(4-fluoro-phenyl) derivatives 3a and 3f substituted with 4-fluorophenyl or 4-fluorostyryl group at the 5-position showed moderate in vitro antiplasmodial activity against this chloroquine-sensitive strain of P. falciparum with IC₅₀ values of 1.43 µM (SI = 0.13) and 2.14 µM (SI = 0.20), respectively. Compound 4a substituted with a trifluoroacetyl group at the 3-position was found to exhibit moderate antiplasmodial activity (IC₅₀ = 2.52 µM, SI = 0.23) compared to the corresponding C-3 unsubstituted precursor 3a (IC₅₀ = 1.43 µM). The presence of a 3-trifluoroacetyl group in 4f, on the other hand, resulted in moderate activity (IC₅₀ = 5.15 µM, SI = 0.47) compared to the corresponding C-3 unsubstituted precursor 3f (IC₅₀ = 2.14 µM). A combination of 2-(4-methoxyphenyl)-, 7-(4-fluorostyryl)- and 3-trifluoroacetyl groups in 4g resulted in appreciable antiplasmodial activity (IC₅₀ = 3.39 µM, SI = 0.31) compared to corresponding substrate 3g, which showed no activity against the parasite (IC₅₀ = 14.03 µM) with the selectivity index of 0.42. The observed increased activity of the 3-trifluoroacetyl derivatives 4 may be due to the electron-withdrawing effect of the trifluoromethyl group (-CF₃) on an indole framework, which has been found to generally increase the lipophilicity, metabolic stability and activity profile compared to that of the 3-unsubstituted or 3-acetyl analogues [1]. These preliminary antiplasmodial activity results also revealed the 4-fluorophenyl or 4-fluorostyryl group as the optimal aryl substituent at the 5-position of the indole framework of compounds 3 and 4. It has been demonstrated that a fluorine atom on the aromatic ring generally increase biological activity of the molecule due to its enhanced lipophilicity [23] and its strong polar interaction with the protein cavity [24]. We took into account that some of the most active antimalarial drugs are nephrotoxic [25] and then screened the four most active compounds 3a, 3f, 4a and 4g for toxicity against monkey kidney Vero cells.

2.2.2. Evaluation of Cytotoxicity against Vero Cells

The four compounds 3a, 3f, 4a and 4g were evaluated for their in vitro cytotoxic effects against monkey kidney Vero cells using the well-established 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide-based colorimetric cell viability (MTT) assay. The LC₅₀ values (lethal concentration at which 50% of the cells are killed) of the four compounds (average from three independent experiments) are listed in

Table 2. Cytotoxic effects of 3a, 3f, 4a and 4g against Monkey kidney Vero cell line.

Compound	LC50 (µM)
3a	13.78 ± 1.29 0.07
3f	>100
4a	32.69 ± 3.63
4g	>100
Doxorubicin hydrochloride	1.53 ± 0.22

. The LC₅₀ values of the four compounds ranged from more than 100 µM to 13.78 µM. Overall, all four compounds had low toxicity at the highest concentrations tested.

The development of a new class of drugs that acts through different mechanism of action is of great importance to circumvent the increasing resistance of P. falciparum to existing antimalarial agents. To help us understand the observed antiplasmodial activity of compounds 3 and 4 and guide further structure activity relationship (SAR) studies we conducted molecular docking of 3a, 3f, 4a and 4g against lactate dehydrogenase (pLDH).

2.3. Molecular Docking Studies of Compounds 3(a,f) and 4(a,g)

4-Hydroxy-1,2,5-oxazole-3-carboxylic acid (OXQ) is the inhibitor for pLDH and co-crystalized with pLDH [26]. The control docking of OXQ has root mean square deviation (RMSD) of 0.4 Å (

Table 3. Estimated binding free energy and hydrogen bond of ligands with parasite lactase dehydrogenase (pLDH) calculated from docking simulation.

Ligand	Hb Distance (Å)	Interacting Atom	FEB (kcal/mol)	RMSD (Å)
OXQ (docked)	1.8	ASN140 2HD2–OXQ O7	−7.11	0.4
	1.8	ARG109 HE–OXQ O7
	1.8	ARG171 2HH1–OXQ O9
	1.9	ARG109 2HH2–OXQ O8
	2.0	HIS195 HE2–OXQ O7
	2.2	ARG171 2HH2–OXQ O8
	2.3	NAD O2D–OXQ H5
	2.5	HIS195 HE2–OXQ O8
	2.7	ARG171 2HH2–OXQ O9
Lactate (LAC)	1.8	ARG171 2HH1–LAC O2	−5.28	-
	1.8	ARG171 2HH2–LAC O1
	1.8	HIS195 HE2–LAC O3
	1.9	ARG109 HE–LAC O3
	2.0	ARG109 2HH2–LAC O1
	2.5	ASN140 2HD2–LAC O3
	2.7	HIS195 HE2–LAC O1
3a	2.1	NAD O1A–3a HN1	−5.95	-
	2.3	NAD O1A–3a HN2
3f	2.2	LYS102 HN–3f O1	−6.46	-
	2.7	THR101 HN–3f O1
4a	2.0	GLY99 O–4a HN2	−6.49	-
4g	2.2	LYS102 HZ3–4g O2	−6.40	-

FEB: Free energy of binding.

) with the crystal structure showing the appropriateness of the parameters used in this docking simulation. Table 3 also shows that the calculated binding free energy for OXQ and lactate (the substrate pLDH) was −7.11 and −5.58 kcal/mol, respectively. This could be due to the fact that OXQ formed 9 hydrogen bonds, but lactate has only 7 hydrogen bond interaction with pLDH/NAD+ (Table 3). In addition, lactate was docked at the same binding site with OXQ, which was near to the nicotinamide region of NAD+ (Figure 3). This has further demonstrated that OXQ is able to compete with lactate for the binding site and thus inhibit pLDH. However, compounds 3(a,f) and 4(a,g) were docked near to the adenine region of NAD+ (Figure 3). The binding free energy of 3f and 4(a,g) were comparable (~−6.4 kcal/mol) while 3a has the weakest binding free energy (−5.95 kcal/mol) (Table 3). Two hydrogen bonds were detected in 3(a,f) while 4(a,g) have only one hydrogen bond. NAD+ is the co-factor of pLDH and the nicotinamide region was buried deep into the core of pLDH with relatively narrow channel. Crystal structure of the complex between chloroquine and P. falciparum lactate dehydrogenase has previously shown this drug within the NADH binding pocket of the enzyme occupying a position similar to that of the adenyl ring of the cofactor [27]. Molecular docking of chloroquine and quinoline-based derivatives into the glycolytic enzyme lactate dehydrogenase, on the other hand, showed that these compounds only bind to this site in the absence of the bound NADH during docking and prefer adenine region of NAD+ which is near to the pLDH surface [28]. Compounds 3(a,f) and 4(a,g) were also unable to access the narrow channel of the NAD+ binding site and resulted to be docked at the adenine region of NAD+ which is near to the pLDH surface. Compound 3a is the only test compound to form hydrogen bonding with NAD+ but other test compounds interacted and formed hydrogen bonding with pLDH. It is also noted that both fluorophenyl ring ends of 3a, 3f and 4g were in parallel with the phosphate region to adenine region of NAD+. Therefore, ring stacking interactions of fluorophenyl ring in 3(a,f) and 4g with adenine region of NAD+ was noticed. However, only the acetyl region of compound 4a was positioned towards the adenine region of NAD+ with other region pointed away from NAD+.

3. Experimental

3.1. General Information

Melting points were recorded on a Thermocouple digital melting point apparatus (Stuart, Staffordshire, UK) and are uncorrected. IR spectra were recorded as powders using a Bruker VERTEX 70 FT-IR Spectrometer (Bruker Optics, Billerica, MA, USA) with a diamond ATR (attenuated total reflectance) accessory by using the thin-film method. For column chromatography, Merck kieselgel 60 (0.063–0.200 mm) (Merck KGaA, Frankfurt, Germany) was used as stationary phase. NMR spectra were obtained as DMSO-d₆ solutions using Varian 300 MHz NMR spectrometer (Varian Inc., Palo Alto, CA, USA) and the chemical shifts are quoted relative to the TMS peak. Low- and high-resolution mass spectra were recorded using Waters Synapt G2 Quadrupole Time-of-flight mass spectrometer (Waters Corp., Milford, MA, USA) at the University of Stellenbosch Mass Spectrometry Unit. The synthesis and characterization of compounds 1a–g have been described before [11].

3.2. Typical Procedure for the Synthesis of Oxime Derivatives 2a–g

A stirred mixture of 1 (1 equivalent) and hydroxylamine hydrochloride (1.5 equivalent) and pyridine (1.5 equivalent) in ethanol (10 mL/mmol of 1) was heated at 80 °C overnight. The mixture was cooled to room temperature and quenched with an ice-cold water and the product was extracted into chloroform. The combined organic phases were washed with water and dried over anhyd. MgSO₄. The salt was filtered off and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (20% EtOAc–hexane as eluent) to afford the oxime derivative 2. The following compounds were prepared in this fashion:

1-(2,5-bis(4-Fluorophenyl)-1H-indol-7-yl) Ethanone Oxime (2a). A mixture of 1a (0.15 g, 0.43 mmol), hydroxylamine hydrochloride (0.05 g, 0.65 mmol) and pyridine (0.05 g, 0.65 mmol) in ethanol (10 mL) afforded 2a as a solid (0.15 g, 94%), R_f 0.67, mp. 238–241 °C; ν_max (ATR) 462, 509, 539, 612, 663, 753, 785, 813, 826, 867, 921, 990, 1099, 1159, 1221, 1232, 1262, 1290, 1373, 1433, 1469, 1514, 3215, 3422 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.38 (3H, s, CH₃), 6.99 (1H, s, 3-H), 7.26 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.33 (2H, t, J = 9.0 Hz, 3′,5′-H), 7.58 (1H, d, J = 1.2 Hz, 4-H), 7.74 (2H, dd, J = 5.7 and 8.7 Hz, 2″,6″-H), 7.81–7.87 (3H, m, 6-H and 2′,6′-H), 10.85 (1H, s, NH), 11.43 (1H, s, OH); ¹³C-NMR (DMSO-d₆) 11.3, 100.1, 116.0 (d, ²J_CF = 21.8 Hz), 116.5 (d, ²J_CF = 21.8 Hz), 119.8, 120.3, 120.6, 127.4 (d, ³J_CF = 8.0 Hz), 128.6 (d, ⁴J_CF = 3.5 Hz), 129.2 (d, ³J_CF = 8.0 Hz), 130.2, 131.8, 133.4, 137.7, 138.3 (d, ⁴J_CF = 3.5 Hz), 155.0, 161.9 (d, ¹J_CF = 241.7 Hz), 162.3 (d, ¹J_CF = 243.9 Hz); HRMS (ES): MH⁺, found 363.1309. C₂₂H₁₇N₂F₂O⁺ requires: 363.1309.

1-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-1H-indol-7-yl) Ethanone Oxime (2b). A mixture of 1b (0.15 g, 0.42 mmol), hydroxylamine hydrochloride (0.04 g, 0.62 mmol) and pyridine (0.05 g, 0.62 mmol) in ethanol (10 mL) afforded 2b as a solid (0.14 g, 87%), R_f 0.47, mp. 212–214 °C; ν_max (ATR) 433, 518, 541, 554, 615, 664, 692, 752, 784, 827, 921, 986, 1021, 1158, 1182, 1217, 1240, 1315, 1371, 1436, 1464, 1513, 3226, 3405 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.39 (3H, s, CH₃), 3.80 (3H, s, CH₃), 6.88 (1H, s, 3-H), 7.05 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.27 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.57 (1H, d, J = 1.2 Hz, 4-H), 7.72–7.89 (5H, m, 6-H, 2′,6′-H and 2″,6″-H), 10.76 (1H, s, NH), 11.43 (1H, s, OH); ¹³C-NMR (DMSO-d₆) 11.3, 55.7, 98.8, 115.0, 116.0 (d, ²J_CF = 20.6 Hz), 119.5, 119.9, 120.2, 124.6, 126.7, 129.1 (d, ³J_CF = 8.0 Hz), 130.4, 131.6, 133.1, 138.4 (d, ⁴J_CF = 3.4 Hz), 138.7, 155.1, 159.6, 161.8 (d, ¹J_CF = 241.7 Hz); HRMS (ES): MH⁺, found: 375.1507. C₂₃H₂₀N₂FO₂⁺ requires: 375.1509.

1-(2-(4-Fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl)ethanone Oxime (2c). A mixture of 1c (0.15 g, 0.43 mmol), hydroxylamine hydrochloride (0.04 g, 0.62 mmol) and pyridine (0.05 g, 0.62 mmol) in ethanol (10 mL) afforded 2c as a solid (0.14 g, 88%), R_f 0.58, mp. 219–222 °C; ν_max (ATR) 512, 561, 613, 664, 692, 753, 789, 826, 921, 989, 1023, 1099, 1156, 1182, 1240, 1272, 1371, 1427, 1466, 1520, 3369, 3406 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.37 (3H, s, CH₃), 3.77 (3H, s, OCH₃), 6.96 (1H, s, 3-H), 7.00 (2H, d, J = 8.7 Hz, 3″,5″-H), 7.33 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.56 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, d, J = 8.1 Hz, 2″,6″-H), 7.76 (1H, d, J = 1.2 Hz, 6-H), 7.84 (2H, d, J = 8.7 Hz, 2′,6′-H), 10.81 (1H, s, NH), 11.41 (1H, s, OH); ¹³C-NMR (DMSO-d₆) 11.3, 55.6, 100.1, 114.7, 116.5 (d, ²J_CF = 21.8 Hz), 119.2, 120.1, 120.5, 127.3 (d, ³J_CF = 9.2 Hz), 128.3, 128.7 (d, ⁴J_CF = 3.5 Hz), 130.2, 132.5, 133.1, 134.2, 137.5, 155.0, 158.7, 162.2 (d, ¹J_CF = 242.8 Hz); HRMS (ES): MH⁺, found: 375.1509. C₂₃H₂₀N₂FO₂⁺ requires: 375.1509.

1-(2,5-Bis(4-methoxyphenyl)-1H-indol-7-yl)ethanone Oxime (2d). A mixture of 1d (0.15 g, 0.40 mmol), hydroxylamine hydrochloride (0.04 g, 0.61 mmol) and pyridine (0.05 g, 0.61 mmol) in ethanol (10 mL) afforded 2d as a solid (0.14 g, 88%), R_f 0.38, mp. 209–212 °C; ν_max (ATR) 545, 615, 663, 752, 784, 818, 828, 838, 921, 986, 1028, 1114, 1176, 1236, 1370, 1434, 1466, 1516, 3390, 3416 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.37 (3H, s, CH₃), 3.78 (3H, s, OCH₃), 3.80 (3H, s, OCH₃), 6.87 (1H, d, s, 3-H), 7.00 (2H, d, J = 8.7 Hz, 3″,5″-H), 7.05 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.53 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, d, J = 8.7 Hz, 2″,6″-H), 7.72 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.74 (1H, d, J = 1.2 Hz, 6-H), 10.71 (1H, s, NH), 11.40 (1H, s, OH); ¹³C-NMR (DMSO-d₆) 11.2, 55.6, 55.7, 98.7, 114.7, 115.0, 119.0, 119.8, 120.0, 124.7, 126.6, 128.3, 130.4, 132.4, 134.4, 138.5, 155.1, 158.7, 159.5; HRMS (ES): MH⁺, found: 387.1714. C₂₄H₂₃N₂O₃⁺ requires: 387.1709.

1-(5-(4-Fluorophenyl)-2-phenyl)-1H-indol-7-yl)ethanone Oxime (2e). A mixture of 1e (0.15 g, 0.42 mmol), hydroxylamine hydrochloride (0.04 g, 0.63 mmol) and pyridine (0.05 g, 0.63 mmol) in ethanol (10 mL) afforded 2e as a solid (0.12 g, 76%), R_f 0.58, mp. 197–199 °C; ν_max (ATR) 484, 508, 533, 605, 684, 735, 785, 841, 885, 952, 989, 1027, 1137, 1153, 1228, 1274, 1360, 1376, 1449, 1507, 3218, 3412 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.39 (3H, s, CH₃), 6.98 (1H, d, s, 3-H), 7.19 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.27–7.37 (3H, m, 2x CH=C and 4′-H), 7.48 (2H, t, J = 7.5 Hz, 3′,5′-H), 7.63 (2H, d, J = 8.7 Hz, 2″,6″-H), 7.69 (1H, d, J = 1.2 Hz, 4-H), 7.78–7.80 (3H, m, 6-H and 2′,6′-H), 10.89 (1H, s, NH), 11.46 (1H, s, OH); ¹³C-NMR (DMSO-d₆) 11.2, 100.0, 116.0 (d, ²J_CF = 21.8 Hz), 120.0, 120.1, 120.2, 125.2 (2 × C), 128.3, 128.4 (d, ³J_CF = 8.0 Hz), 129.4, 129.5, 129.9, 130.0, 131.9, 133.7, 134.7 (d, ⁴J_CF = 2.3 Hz), 138.4, 155.0, 161.8 (d, ¹J_CF = 242.8 Hz); HRMS (ES): MH⁺, found: 371.1568. C₂₃H₂₀N₂FO₂⁺ requires: 371.1560.

1-(2-(4-Fluorophenyl)-5-(4-fluorostyryl)-1H-indol-7-yl)ethanone Oxime (2f). A mixture of 1f (0.15 g, 0.40 mmol), hydroxylamine hydrochloride (0.04 g, 0.60 mmol) and pyridine (0.05g, 0.60 mmol) in ethanol (10 mL) afforded 2f as a solid (0.12 g, 75%), R_f 0.67, mp. 238‒240 °C; ν_max (ATR) 480, 509, 540, 578, 667, 718, 745, 772, 784, 805, 832, 881, 949, 988, 1097, 1154, 1223, 1286, 1376, 1431, 1467, 1505, 3234, 3409 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.37 (3H, s, CH₃), 6.95 (1H, d, s, 3-H), 7.19 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.29 (2H, d, J = 17.0 Hz, CH=CH), 7.31 (2H, d, J = 16.2 Hz, CH=CH), 7.32 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.63 (2H, d, J = 8.7 Hz, 2″,6″-H), 7.67 (1H, d, J = 1.2 Hz, 4-H), 7.77 (1H, d, J = 1.2 Hz, 6-H), 7.83 (2H, d, J = 8.7 Hz, 2′,6′-H), 10.85 (1H, s, NH), 11.42 (1H, s, OH); ¹³C-NMR (DMSO-d₆) 11.3, 100.0, 116.0 (d, ²J_CF 21.8 Hz), 116.5 (d, ²J_CF = 21.8 Hz), 120.1 (2 × C), 120.2, 125.2, 127.3 (d, ³J_CF = 8.0 Hz), 128.3 (d, ³J_CF = 8.0 Hz), 128.6 (d, ⁴J_CF = 3.4 Hz), 129.5, 129.9, 130.0, 133.7, 134.7 (d, ⁴J_CF = 3.5 Hz), 137.6, 154.9, 161.8 (d, ¹J_CF = 242.8 Hz), 162.2 (d, ¹J_CF = 243.9 Hz); HRMS (ES): MH⁺, found: 389.1465. C₂₄H₁₉N₂F₂O⁺ requires: 389.1465.

1-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-1H-indol-7-yl)ethanone Oxime (2g). A mixture of 1f (0.15 g, 0.39 mmol), hydroxylamine hydrochloride (0.04 g, 0.59 mmol) and pyridine (0.05 g, 0.59 mmol) in ethanol (10 mL) afforded 2f as a solid (0.11 g, 76%), R_f 0.47, mp. 220–222 °C; ν_max (ATR) 462, 507, 584, 606, 666, 715, 745, 786, 830, 838, 881, 960, 989, 1020, 1179, 1224, 1249, 1355, 1435, 1467, 1499, 3423, 3461 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.37 (3H, s, CH₃), 3.80 (3H, s, OCH₃), 6.85 (1H, s, 3-H), 7.04 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.19 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.23 (2H, d, J = 16.5 Hz, CH=CH), 7.32 (2H, d, J = 16.5 Hz, CH=CH), 7.61‒7.66 (3H, m, 4-H and 2″,6″-H), 7.71 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.75 (1H, d, J = 1.2 Hz, 6-H), 10.75 (1H, s, NH), 11.41 (1H, s, OH); ¹³C-NMR (DMSO-d₆) 11.3, 55.7, 98.7, 115.0 (2 × C), 116.0 (d, ²J_CF = 21.8 Hz), 119.8, 119.9, 124.6, 125.0, 126.6, 128.3 (d, ³J_CF = 8.0 Hz), 129.3, 130.0, 130.2, 133.5, 134.7 (d, ⁴J_CF = 3.4 Hz), 138.6, 155.0, 159.6, 161.8 (d, ¹J_CF = 241.6 Hz); HRMS (ES): MH⁺, found: 401.1664. C₂₅H₂₂N₂FO₂⁺ requires: 401.1665.

3.3. Typical Procedure for the Beckmann Rearrangement of 3a–g

A stirred mixture of 2 (1 equivalent) and TFA (1 equivalent) in acetonitrile (20 mL/mmol of 2) was heated at 80 °C for 2 h. The mixture was cooled to room temperature and quenched with ice-cold water. The product was extracted with chloroform (3 × 20 mL) and the combined organic layers were dried over anhydrous MgSO₄ and the salt was filtered off. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on a silica gel (60% EtOAc–hexane as eluent) to afford 3 as a solid. Products 3a–f were prepared in this fashion:

N-(2,5-Bis(4-fluorophenyl)-1H-indol-7-yl) Acetamide (3a). A mixture of 2a (0.10 g, 0.28 mmol) and TFA (0.03 g, 0.28 mmol) in acetonitrile (5 mL) afforded 3a as solid (0.08 g, 80%); R_f 0.51, mp. 272–275 °C; ν_max (ATR) 459, 509, 538, 595, 653, 753, 795, 810, 828, 1010, 1102, 1159, 1218, 1230, 1280, 1433, 1474, 1513, 1549, 1630, 1653, 3243, 3339 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.19 (3H, s, CH₃), 6.92 (1H, s, 3-H), 7.25 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.34 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.53 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, d, J = 8.7 Hz, 2″,6″-H), 7.85–7.90 (3H, m, 6-H and 2′,6′-H), 9.73 (1H, s, NH), 11.10 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.5, 100.3, 113.3, 114.6, 116.0 (d, ²J_CF = 21.8 Hz), 116.1, 116.4 (d, ²J_CF = 20.6 Hz), 124.4, 127.6 (d, ³J_CF = 8.0 Hz), 128.8 (d, ⁴J_CF = 3.4 Hz), 128.9 (d, ³J_CF = 8.0 Hz), 130.9, 131.8, 137.6, 138.5 (d, ⁴J_CF = 2.3 Hz), 161.8 (d, ¹J_CF = 241.6 Hz), 162.2 (d, ¹J_CF = 242.8 Hz), 169.0; HRMS (ES): MH⁺, found: 363.1311. C₂₂H₁₇N₂F₂O⁺ requires: 363.1231.

N-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3b). A mixture of 2b (0.10 g, 0.27 mmol) and TFA (0.03 g, 0.27 mmol) in acetonitrile (5 mL) afforded 3b as a solid (0.08 g, 75%); R_f 0.37, mp. 213–215 °C; ν_max (ATR) 518, 533, 595, 745, 774, 811, 831, 1025, 1101, 1177, 1226, 1253, 1367, 1390, 1426, 1472, 1516, 1553, 1609, 1654, 3316 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.20 (3H, s, CH₃), 3.80 (3H, s, OCH₃), 6.80 (1H, s, 3-H), 7.06 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.25 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.49 (1H, d, J = 1.2 Hz, 4-H), 7.62 (2H, t, = 8.7 Hz, 2″,6″-H), 7.76 (2H, d, J = 8.7 Hz 2′,6′-H), 7.87 (1H, d, J = 1.2 Hz, 6-H), 9.72 (1H, s, NH), 11.01 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.5, 55.7, 99.0, 112.7, 114.2, 114.9, 116.0 (d, ²J_CF 20.6 Hz), 124.3, 124.9, 126.9, 128.4, 128.8 (d, ³J_CF 8.0 Hz), 131.1, 131.6, 138.6 (d, ⁴J_CF 3.5 Hz), 159.5, 161.7 (d, ¹J_CF 241.7 Hz), 169.0; HRMS (ES): MH⁺, found: 375.1510. C₂₃H₂₀N₂FO₂⁺ requires: 375.1509.

N-(2-(4-Fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3c). A mixture of 2c (0.10 g, 0.27 mmol) and TFA (0.03 g, 0.27 mmol) in acetonitrile (5 mL) afforded 3c as a solid (0.07 g, 73%); R_f 0.47, mp. 216–218 °C; ν_max (ATR) 505, 523, 550, 600, 719, 749, 786, 805, 826, 1032, 1159, 1178, 1231, 1371, 1427, 1480, 1516, 1566, 1631, 1654, 3258, 3320 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.19 (3H, s, CH₃), 3.77 (3H, s, OCH₃), 6.90 (1H, s, 3-H), 6.99 (2H, d, J = 8.4 Hz, 3″,5″-H), 7.34 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.48 (1H, d, J = 1.2 Hz, 4-H), 7.53 (2H, t, J = 8.4 Hz, 2″,6″-H), 7.84–7.89 (3H, m, 6-H and 2′,6′-H), 9.71 (1H, s, NH), 11.04 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.5, 55.6, 100.2, 113.2, 114.0, 114.7, 116.4 (d, ²J_CF = 20.6 Hz), 124.3, 127.5 (d, ³J_CF = 8.0 Hz), 128.1, 128.5, 129.1 (d, ⁴J_CF = 3.5 Hz), 130.9, 132.6, 134.5, 137.4, 158.6, 162.1 (d, ¹J_CF = 242.8 Hz), 169.0; HRMS (ES): MH⁺, found: 375.1508. C₂₃H₂₀N₂FO₂⁺ requires: 375.1509.

N-(2,5-Bis(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3d). A mixture of 2d (0.10 g, 0.26 mmol) and TFA (0.03 g, 0.26 mmol) in acetonitrile (5 mL) afforded 3d as a solid (0.07 g, 70%); R_f 0.31, mp. 236–239 °C; ν_max (ATR) 529, 564, 600, 723, 775, 830, 1030, 1112, 1176, 1244, 1280, 1372, 1432, 1440, 1514, 1550, 1605, 1632, 1656, 3269, 3321 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.19 (3H, s, CH₃), 3.77 (3H, s, OCH₃), 3.80 (3H, s, OCH₃), 6.79 (1H, s, 3-H), 6.99 (2H, d, J = 9.0 Hz, 3″,5″-H), 7.06 (2H, d, J = 8.1 Hz, 3′,5′-H), 7.45 (1H, d, J = 1.2 Hz, 4-H), 7.53 (2H, d, J = 8.4 Hz, 2″,6″-H), 7.76 (2H, d, J = 8.7 Hz 2′,6′-H), 7.83 (1H, d, J = 1.2 Hz, 6-H), 9.70 (1H, s, NH), 10.96 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.5, 55.6, 55.7, 98.9, 112.6, 113.7, 114.7, 114.9 (2 × C), 124.2, 125.0, 126.9, 128.0, 131.1, 132.4, 134.6, 138.4, 158.6, 159.4, 168.9; HRMS (ES): MH⁺, found: 387.1708. C₂₄H₂₃N₂O₃⁺ requires: 387.1709.

(E)-N-(5-(4-Fluorostyryl)-2-phenyl-1H-indol-7-yl) Acetamide (3e). A mixture of 2e (0.10 g, 0.27 mmol) and TFA (0.03 g, 0.27 mmol) in acetonitrile (5 mL) afforded 3e as a solid (0.08 g, 78%); R_f 0.51, mp. 262–264 °C; ν_max (ATR) 481, 512, 564, 598, 689, 738, 756, 799, 814, 847, 957, 1158, 1204, 1223, 1286, 1353, 1455, 1507, 1646, 3267, 3299 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.18 (3H, s, CH₃), 6.90 (1H, s, 3-H), 7.03 (1H, d, J = 16.5 Hz, CH=CH), 7.16 (2H, t, J = 8.4 Hz, 3″,5″-H), 7.22 (1H, d, J = 16.5 Hz, CH=CH), 7.33–7.35 (1H, m, 4′-H), 7.45–7.48 (3H, m, 4-H and 2″,6″-H), 7.46–7.59 (2H, m, 3′,5′-H), 7.82 (2H, d, J = 7.8 Hz, 2′,6′-H) 7.88 (1H, d, J = 1.2 Hz, 6-H), 9.70 (1H, s, NH), 11.12 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.5, 100.2, 112.4, 115.7, 115.9 (d, ²J_CF = 20.6 Hz), 124.3, 124.7, 125.5, 128.3, 128.2 (d, ³J_CF = 8.0 Hz), 128.4, 129.3, 129.4, 129.5, 130.4, 130.5, 132.3, 134.6 (d, ⁴J_CF = 2.3 Hz), 138.4, 161.7 (d, ¹J_CF = 242.8 Hz), 170.0; HRMS (ES): MH⁺, found: 371.1554. C₂₄H₂₀N₂FO⁺ requires: 371.1560.

(E)-N-(2-(4-Fluorophenyl)-5-(4-fluorostyryl)-1H-indol-7-yl) Acetamide (3f). A mixture of 2f (0.10 g, 0.28 mmol) and TFA (0.03 g, 0.28 mmol) in acetonitrile (5 mL) afforded 3f as a solid (0.08 g, 77%), R_f 0.51, mp. 278–280 °C; ν_max (ATR) 467, 509, 552, 581, 609, 761, 789, 831, 848, 957, 1012, 1099, 1159, 1221, 1232, 1352, 1441, 1477, 1502, 1545, 1652, 3257, 3301 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.19 (3H, s, CH₃), 6.88 (1H, s, 3-H), 7.04 (2H, d, J = 16.5 Hz, CH=CH), 7.18 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.23 (2H, d, J = 16.5 Hz, CH=CH), 7.34 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.49 (1H, d, J = 1.2 Hz, 4-H), 7.63 (2H, t, J = 8.7 Hz, 2″,6″-H), 7.84–7.89 (3H, m, 6-H and 2′,6′-H), 9.68 (1H, s, NH), 11.08 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.4, 100.2, 110.0, 112.7, 115.9 (d, ²J_CF = 21.8 Hz), 116.4 (d, ²J_CF = 20.6 Hz), 124.2, 124.7, 127.6 (d, ³J_CF = 9.1 Hz), 128.3 (d, ³J_CF = 8.0 Hz), 128.9 (d, ⁴J_CF = 2.3 Hz), 129.5, 129.6, 130.3, 130.6, 134.6 (d, ⁴J_CF = 2.3 Hz), 137.5, 161.7 (d, ¹J_CF = 241.6 Hz), 162.2 (d, ¹J_CF = 243.9 Hz), 169.0; HRMS (ES): MH⁺, found: 389.1465. C₂₄H₁₉N₂F₂O⁺ requires: 389.1465.

(E)-N-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (3g). A mixture of 2g (0.10 g, 0.25 mmol) and TFA (0.03 g, 0.25 mmol) in acetonitrile (5 mL) afforded 3g as a solid (0.07 g, 69%); R_f 0.33, mp. 233–235 °C; ν_max (ATR) 488, 516, 549, 584, 614, 746, 786, 809, 830, 843, 954, 1025, 1095, 1159, 1181, 1223, 1253, 1276, 1346, 1371, 1460, 1502, 1554, 1609, 1646, 3298 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.18 (3H, s, CH₃), 3.80 (3H, s, OCH₃), 6.77 (1H, d, s, 3-H), 7.02 (1H, d, J = 15.9 Hz, CH=CH) 7.05 (2H, d, J = 8.1 Hz, 3′,5′-H), 7.17 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.22 (2H, d, J = 15.9 Hz, CH=CH), 7.45 (1H, d, J = 1.2 Hz, 4-H), 7.62 (2H, d, J = 8.7 Hz, 2″,6″-H), 7.75 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.82 (1H, d, J = 1.2 Hz, 6-H), 9.66 (1H, s, NH), 10.99 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.5, 55.7, 98.9, 112.1, 114.9, 115.4, 115.9 (d, ²J_CF = 21.8 Hz), 124.1, 124.6, 124.9, 126.9, 128.3 (d, ³J_CF = 8.0 Hz), 129.1, 129.3, 130.5 130.8, 134.6 (d, ⁴J_CF = 3.4 Hz), 138.6, 159.5, 161.7 (d, ¹J_CF = 242.8 Hz), 170.0; HRMS (ES): MH⁺, found: 401.1658. C₂₅H₂₂N₂FO₂⁺ requires: 401.1665.

3.4. Typical Procedure for the Trifluoroacetylation of 3a–g

A mixture of 3 (1 equivalent) and TFAA (1.5 equivalent) in THF (25 mL/mmol of 3) was heated at 60 °C for 5 h. The mixture was cooled to room temperature quenched with saturated sodium hydrogen carbonate solution. The mixture was extracted with chloroform (3 × 20 mL) and the combined organic layers were dried with anhydrous MgSO₄ and the salt was filtered off. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on a silica gel (60% EtOAc–hexane as eluent) to afford 4 as a solid. Compounds 4a–g were prepared in this fashion.

N-(2,5-Bis(4-fluorophenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4a). A mixture of 3a (0.15 g, 0.41 mmol) and TFAA (0.13 g, 0.62 mmol) in THF (10 mL) afforded 4a as a solid (0.15 g, 79%), R_f 0.51, mp. 215–218 °C; ν_max (ATR) 436, 514, 565, 589, 644, 721, 744, 814, 832, 900, 927, 1013, 1041, 1098, 1143, 1186, 1202, 1225, 1374, 1436, 1513, 1605, 1634, 1653, 3251, 3312 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.13 (3H, s, CH₃), 7.30 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.40 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.61–7.72 (4H, m, 2′,6′-H and 2″,6″-H), 7.91 (1H, d, J = 1.2 Hz, 4-H), 8.02 (1H, d, J = 1.2 Hz, 6-H), 9.83 (1H, s, NH), 12.47 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.2, 108 .1, 115.6 (d, ²J_CF = 21.8 Hz), 116.2 (d, ²J_CF = 21.8 Hz), 116.3, 116.7 (q, ¹J_CF = 288.6 Hz), 125.2, 127.9 (d, ⁴J_CF = 3.5 Hz), 128.2, 128.7, 129.2 (d, ³J_CF = 8.0 Hz), 132.8 (d, ³J_CF = 8.0 Hz), 135.6, 137.9 (d, ⁴J_CF = 2.3 Hz), 148.2, 162.2 (d, ¹J_CF = 242.8 Hz), 163.6 (d, ¹J_CF = 246.2 Hz), 169.2, 170.8, 175.7 (q, ²J_CF = 34.4 Hz); ¹⁹F-NMR (DMSO-d₆) -115.9 (1F, ddd, J = 5.9, 8.7 and 14.7 Hz, 4′′-CF), −110.5 (1F, ddd, J = 4.8, 8.7 and 13.8 Hz, 4′-CF), −71.2 (3F, s, COCF₃); HRMS (ES): MH⁺, found 459.1131. C₂₄H₁₆ N₂F₅O₂⁺ requires: 459.1132.

N-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4b). A mixture of 3b (0.15 g, 0.40 mmol) and TFAA (0.13 g, 0.60 mmol) in THF (10 mL) afforded 4b as a solid (0.15 g, 86%), R_f 0.34, mp. 222–224 °C; ν_max (ATR) 417, 517, 539, 569, 594, 713, 722, 834, 912, 963, 1014, 1038, 1144, 1180, 1206, 1249, 1291, 1435, 1473, 1513, 1612, 1634, 1654, 1676, 3209, 3276 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.13 (3H, s, CH₃), 3.84 (3H, s, OCH₃), 7.11 (2H, d, J = 8.4 Hz, 3′,5′-H), 7.30 (2H, t, J = 8.7 Hz, 3″,5″-H), 7.57 (2H, d, J = 8.4 Hz, 2′,6′-H), 7.63 (2H, t, J = 8.7 Hz, 2″,6″-H), 7.91 (1H, d, J = 1.2 Hz, 4-H), 7.99 (1H, d, J = 1.2 Hz, 6-H), 9.80 (1H, s, NH), 12.33 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.2, 55.8, 107.7, 114.1 (2 × C), 115.0, 115.9, 116.2 (d, ²J_CF = 20.6 Hz), 116.8 (q, ¹J_CF J = 288.5 Hz), 123.7, 125.1, 127.9, 129.0, 129.2 (d, ³J_CF = 8.0 Hz), 131.8, 135.4, 138.0 (d, ⁴J_CF = 3.4 Hz), 149.4, 161.1, 162.1 (d, ¹J_CF = 242.8 Hz), 169.2, 176.0 (q, ²J_{CF =} 35.5 Hz); ¹⁹F-NMR (DMSO-d₆) −116.0 (1F, ddd, J = 5.9, 9.0 and 14.9 Hz, 4″-CF), −71.0 (3F, s, COCF₃); HRMS (ES): MH⁺, found: 471.1333. C₂₅H₁₉N₂F₄O₃⁺ requires: 471.1332.

N-(3-(2,2,2-Trifluoroacetyl)-2-(4-fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (4c). A mixture of 3c (0.15 g, 0.40 mmol) and TFAA (0.13 g, 0.60 mmol) in THF (10 mL) afforded 4c as a solid (0.17 g, 89%), R_f 0.42, mp. 255–257 °C; ν_max (ATR) 448, 504, 517, 545, 592, 624, 643, 729, 783, 808, 832, 850, 901, 929, 1019, 1123, 1157, 1180, 1219, 1244, 1302, 1369, 1448, 1515, 1566, 1604, 1632, 1657, 3185, 3245 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.11 (3H, s, CH₃), 3.78 (3H, s, OCH₃), 7.04 (2H, d, J = 7.5 Hz, 3″,5″-H), 7.39 (2H, t, J = 7.5 Hz, 3′,5′-H), 7.55 (2H, d, J = 7.5 Hz, 2″,6″-H), 7.65–7.70 (2H, m, 2′,6′-H), 7.87 (1H, d, J = 1.2 Hz, 4-H), 7.99 (1H, d, J = 1.2 Hz, 6-H), 9.84 (1H, s, NH), 12.44 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.1, 55.6, 108.0, 114.5, 114.9, 115.6 (d, ²J_CF = 21.8 Hz), 116.1, 116.8 (q, ¹J_CF = 288.5 Hz), 125.2, 127.9, 128.0 (d, ⁴J_CF = 3.5 Hz), 128.3, 128.7, 132.8 (d, ³J_CF = 9.1 Hz), 133.8, 136.4, 148.1, 159.2, 163.5 (d, ¹J_CF = 246.2 Hz), 169.3, 175.7 (q, ²J_CF 35.5 Hz); ¹⁹F-NMR (282 MHz, DMSO-d₆) −111.9 (1F, ddd, J 4.8, 8.7 and 14.7 Hz, 4′ -CF), −71.2 (3F, s, COCF₃); HRMS (ES): MH⁺, found 471.1334. C₂₅H₁₉N₂F₄O₃⁺ requires: 471.1332.

N-(2,5-Bis(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4d). A mixture of 3d (0.15 g, 0.39 mmol) and TFAA (0.12 g, 0.58 mmol) in THF (10 mL) afforded 4b as a solid (0.17 g, 90%), R_f 0.28, mp. 254–257 °C; ν_max (ATR) 528, 545, 594, 643, 714, 729, 798, 852, 900, 928, 966, 1026, 1137, 1178, 1201, 1235, 1253, 1295, 1436, 1450, 1516, 1566, 1607, 1655, 1673, 3171, 3251 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.13 (3H, s, CH₃), 3.79 (3H, s, OCH₃), 3.85 (3H, s, OCH₃), 7.05 (2H, d, J = 8.7 Hz, 3″,5″-H), 7.12 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.54 (2H, d, J = 8.4 Hz, 2″,6″-H), 7.57 (2H, d, J = 8.4 Hz, 2′,6′-H), 7.88 (1H, d, J = 1.2 Hz, 4-H), 7.98 (1H, d, J = 1.2 Hz, 6-H), 9.78 (1H, s, NH), 12.28 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.2, 55.6, 55.8, 107.6, 114.1, 114.5, 114.9, 115.8, 116.8 (q, ¹J_CF = 288.6 Hz), 123.7, 125.0, 127.7, 128.1, 128.3, 129.0, 131.8, 133.9, 136.2, 149.2, 159.2, 161.1, 169.2, 175.9 (q, ²J_{CF =} 34.4 Hz); ¹⁹F-NMR (DMSO-d₆) −71.0 (3F, s, COCF₃); HRMS (ES): MH⁺, found: 483.1533. C₂₆H₂₂N₂F₃O₄⁺ requires: 483.1532.

(E)-N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-phenyl-1H-indol-7-yl] Acetamide (4e). A mixture of 3e (0.15 g, 0.41 mmol) and TFAA (0.13g, 0.61 mmol) in THF (10 mL) afforded 4e as a solid (0.15 g, 80%), R_f 0.35, mp. 230–233 °C; ν_max (ATR) 475, 507, 527, 599, 674, 702, 731, 750, 773, 818, 852, 915, 962, 1012, 1141, 1184, 1224, 1260, 1285, 1370, 1434, 1456, 1508, 1558, 1628, 1657, 1667, 3198, 3331 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.12 (3H, s, CH₃), 7.13 (1H, d, J = 16.5 Hz, CH=CH), 7.19 (2H, t, J = 8.1 Hz, 3″,5″-H), 7.37 (1H, d, J = 16.5 Hz, CH=CH), 7.57–8.00 (5H, m, 4′-H, 3′,5′-H, and 2″,6″-H), 7.68–7.72 (2H, m, 2′,6′-H), 7.92 (1H, d, J = 1.2 Hz, 4-H), 8.02 (1H, d, J = 1.2 Hz, 6-H) 9.74 (1H, s, NH), 12.43 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.1, 107.1, 115.4, 116.0 (d, ²J_CF = 21.8 Hz), 116.2, 116.7 (q, ¹J_CF = 288.5 Hz), 124.8, 125.0, 126.6, 128.6, 128.8 (d, ³J_CF = 8.0 Hz), 129.6, 129.7, 130.3, 130.4, 131.6, 133.3, 134.2 (d, ⁴J_CF = 2.3 Hz), 149.0, 162.0 (d, ¹J_CF = 242.8 Hz), 169.2, 176.0 (q, ²J_CF = 35.5 Hz); ¹⁹F-NMR (DMSO-d₆) −114.6 (1F, ddd, J = 5.9, 8.7 and 14.7 Hz, 4″-CF), −71.02 (3F, s, COCF₃); HRMS (ES): MH⁺, found: 467.1384. C₂₆H₁₉N₂F₄O₂⁺ requires: 467.1383.

N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-(4-fluorophenyl)-1H-indol-7-yl] Acetamide (4f). A mixture of 3f (0.15 g, 0.39 mmol) and TFAA (0.12 g, 0.58 mmol) in THF (10 mL) afforded 4f as a solid (0.15 g, 81%), R_f 0.34, mp. 222–225 °C; ν_max (ATR) 478, 514, 524, 578, 624, 733, 785, 816, 845, 920, 964, 1012, 1097, 1156, 1197, 1226, 1301, 1372, 1446, 1507, 1598, 1641, 1657, 3181, 3251 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.12 (3H, s, CH₃), 7.14 (1H, d, J = 16.5 Hz, CH=CH), 7.20 (2H, t, J = 9.3 Hz, 3″,5″-H), 7.37 (1H, d, J = 16.5 Hz, CH=CH), 7.41 (2H, t, J = 8.7 Hz, 3′,5′-H), 7.66–7.73, (4H, m, 2′,6′-H and 2″,6″-H), 7.88 (1H, d, J = 1.2 Hz, 4-H), 8.01 (1H, d, J = 1.2 Hz, 6-H), 9.77 (1H, s, NH), 12.43 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.1, 107.1, 114.8, 115.6 (d, ²J_CF = 21.8 Hz), 116.0 (d, ²J_CF = 20.6 Hz), 116.2, 116.3, 117.0 (q, ¹J_CF = 230.2 Hz), 125.0, 126.6, 128.0 (d, ⁴J_CF 3.5 Hz), 128.6, 128.8 (d, ³J_CF 8.0 Hz), 129.0, 129.6, 132.8 (d, ³J J 8.0 Hz), 133.3, 134.2 (d, ⁴J_CF = 3.5 Hz), 147.9, 162.0 (d, ¹J_CF = 243.9 Hz), 163.5 (d, ¹J_CF = 246.2 Hz), 175.8 (q, ²J_CF = 34.4 Hz); ¹⁹F-NMR (DMSO-d₆) −114.6 (1F, ddd, J = 5.9, 9.0 and 14.9 Hz 4″-CF), −110.9 (1F, ddd, J = 5.9, 9.0 and 14.9 Hz, 4′-CF), −71.2 (3F, s, COCF₃); HRMS (ES): MH⁺, found: 485.1285. C₂₆H₁₈N₂F₅O₂⁺ requires: 485.1288.

((E)-N-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4g). A mixture of 3g (0.15 g, 0.38 mmol) and TFAA (0.12 g, 0.56 mmol) in THF (10 mL) afforded 4g as a solid (0.14 g, 74%), R_f 0.20, mp. 264–267 °C; ν_max (ATR) 466, 527, 613, 633, 730, 749, 749, 817, 817, 846, 893, 922, 964, 1007, 1030, 1046, 1118, 1133, 1177, 1200, 1212, 1229, 1251, 1292, 1369, 1391, 1442, 1506, 1560, 1606, 1653, 1668, 3179, 3240 cm⁻¹; ¹H-NMR (DMSO-d₆) 2.12 (3H, s, CH₃), 3.84 (3H, s, OCH₃), 7.11 (2H, d, J = 8.7 Hz, 3′,5′-H), 7.14‒7.22 (3H, m, CH=CH and 3″,5″-H), 7.36 (1H, d, J = 16.5 Hz, CH=CH), 7.55 (2H, d, J = 8.7 Hz, 2′,6′-H), 7.70 (2H, d, J = 8.7 Hz, 2″,6″-H), 7.89 (1H, d, J = 1.2 Hz, 4-H), 7.99 (1H, d, J = 1.2 Hz, 6-H) 9.74 (1H, s, NH), 12.30 (1H, s, NH); ¹³C-NMR (DMSO-d₆) 24.2, 55.8, 107.7, 114.1 (2 × C), 115.2, 116.0 (d, ²J_CF = 20.6 Hz), 116.7 (q, ¹J_CF J = 289.7 Hz), 123.7, 124.9, 126.5, 128.7, 128.8 (d, ³J_CF = 8.0 Hz), 129.6, 129.7, 131.8, 133.1, 134.2 (d, ⁴J_CF = 2.3 Hz), 149.1, 161.1, 162.0 (d, ¹J_CF = 242.8 Hz), 169.2, 176.1 (q, ²J_CF = 35.6 Hz); ¹⁹F-NMR (DMSO-d₆) -114.6 (1F, ddd, J = 5.9, 9.0 and 14.9 Hz, 4″-CF), -71.0 (3F, s, COCF₃); HRMS (ES): MH⁺, found: 497.1488. C₂₇H₂₁F₄N₂O₃⁺ requires: 497.1488.

3.5. Typical Procedure for the One-pot Sequential Beckmann Rearrangement of 2a–g and Subsequent Trifluoroacetylation

A mixture of 2 (1 equivalent) and TFA (1.2 equivalent) in acetonitrile (25 mL/mmol of 2) was refluxed at 80 °C for 2 h. TFAA (2 equiv.) was added to the mixture and heating was continued for 5 h at this temperature. The solvent was evaporated under reduced pressure and the residue was quenched with an ice-cold water. The product was extracted with chloroform and the combined organic layers were dried over anhydrous MgSO_4. The salt was filtered off and then the solvent was evaporated under reduced pressure on a rotary evaporator. The residue was purified by column chromatography on a silica gel to afford 4 as a solid. Products 4a–f were prepared in this fashion.

N-(2,5-Bis(4-fluorophenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4a). A mixture of 2a (0.15 g, 0.41 mmol) and TFA (0.06 g, 0.50 mmol) in CH₃CN (10 mL) followed by treatment with TFAA (0.17 g, 0.83 mmol) afforded 4a as a solid (0.14 g, 74%).

N-(5-(4-Fluorophenyl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4b). A mixture of 2b (0.15 g, 0.40 mmol) and TFA (0.05 g, 0.48 mmol) in CH₃CN (10 mL) followed by treatment with TFAA (0.17 g, 0.80 mmol) afforded 4b as a solid (0.15 g, 80%).

N-(3-(2,2,2-Trifluoroacetyl)-2-(4-fluorophenyl)-5-(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (4c). A mixture of 2c (0.15 g, 0.40 mmol) and TFA (0.05 g, 0.48 mmol) in CH₃CN (10 mL) followed by treatment with TFAA (0.17 g, 0.80 mmol) afforded 4c as a solid (0.16 g, 82%).

N-(3-(2,2,2-Trifluoroacetyl)-2,5-bis(4-methoxyphenyl)-1H-indol-7-yl) Acetamide (4d). A mixture of 2d (0.15 g, 0.39 mmol) and TFA (0.05 g, 0.47 mmol) in CH₃CN (10 mL) followed by treatment with TFAA (0.16 g, 0.78 mmol) afforded 4d as a solid (0.16 g, 84%).

(E)-N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-phenyl-1H-indol-7-yl] Acetamide (4e). A mixture of 2e (0.15 g, 0.41 mmol) and TFA (0.6 g, 0.48 mmol) in CH₃CN (10 mL) followed by treatment with TFAA (0.17 g, 0.81 mmol) afforded 4e as a solid (0.14 g, 76%).

(E)-N-[5,[5-(4-Fluorostyryl)-3-(2,2,2-trifluoroacetyl)-2-(4-fluorophenyl)-1H-indol-7-yl] Acetamide (4f). A mixture of 2f (0.15 g, 0.39 mmol) and TFA (0.05 g, 0.46 mmol) in CH₃CN (10 mL) followed by treatment with TFAA (0.16 g, 0.77 mmol) afforded 4f as a solid (0.15 g, 79%).

((E)-N-(5-(4-Fluorostyryl)-2-(4-methoxyphenyl)-3-(2,2,2-trifluoroacetyl)-1H-indol-7-yl) Acetamide (4g). A mixture of 2g (0.15 g, 0.38 mmol) and TFA (0.05 g, 0.46 mmol) in CH₃CN (10 mL) followed by treatment with TFAA (0.16 g, 0.75 mmol) afforded 4g as a solid (0.13 g, 72%).

3.6. pLDH Asssay

Three-fold serial dilutions of the test compounds were incubated in triplicates with 3D7 strain P. falciparum parasites in a transparent 96-well flat bottom plate. DMSO and chloroquine were used as negative and positive controls, respectively. The plate was put in an airtight box, gassed and incubated with complete RPMI 1640 medium for 48 h. At the end of incubation, Malstat reagent was added to the 96-well plate followed by developing with NBT/PES (nitro blue tetrazolium + phenazine ethosulphate) reagent. Parasite growth was determined spectrophotometrically at 620 nm, by measuring the activity of the pLDH in control and drug-treated cultures using an Infinite F500 multiwell plate reader (Tecan Group Ltd., Zürich, Switzerland). The OD values from control wells devoid of drug were referred to as having 100% pLDH activity. The IC₅₀ are expressed as the % parasite survival relative to the control, calculated from fitted sigmoidal dose response curves. The dose response curves were obtained by plotting percentage parasite survival against the logarithm of the concentration using the GraphPad Prism software package (GraphPad software Inc., La Jolla, CA, USA). IC₅₀ values were calculated graphically by interpolation from these curves.

3.7. In Vitro Cytotoxicity Assay

Monkey kidney cells (Vero) used in this experiment were obtained from Cellonex (Johannesburg, South Africa). The cells were maintained in Dulbecco’s Modified Eagle’s (DMEM, HyClone, Thermo Scientific, Aalst, Belgium) supplemented with 0.4 mML-glutamine and sodium pyruvate and 10% foetal bovine serum (FBS, HyClone, Thermo Scientific). The cells of a sub-confluent culture were harvested using trypsin-EDTA (HyClone, Thermo Scientific) and centrifuged at 200× g for 5 min and re-suspended in growth medium to 5 × 10⁴ cells/mL. A total of 200 µL of the cell suspension was pipetted into each well of columns 2 to 11 of a 96 well culture plate. The same amount of the growth medium was added to wells of column 1 and 12 to maintain humidity and minimize the edge effect. The plates were incubated at 37 °C in a 5% CO₂ incubator overnight until the cells were in the exponential phase of growth. After incubation, the DMEM was aspirated from the cells and replaced with 200 µL of different concentrations of the test samples (0.1–100 µM). Each dilution of the test sample was tested in quadruplicate in each experiment and the experiments were repeated three times. The plates were again incubated for 2 days at 37 °C in a 5% incubator. A negative control (untreated cells) and positive control (cells treated with different concentrations of doxorubicin hydrochloride, Sigma, Schnelldorf, Germany) were included. After incubation, 30 µL of 5 mg/mL MTT, (Sigma-Aldrich, GmBH, Schnelldorf, Germany) in phosphate buffered saline PBS was added to each well and the plates were incubated for a further 4 h at 37 °C. After incubation with MTT, the medium in each well was removed and the formazan crystals formed were dissolved by adding 50 µL of DMSO to each well of the plates. The plates were gently shaken until the crystals were dissolved. The amount of MTT reduction was measured immediately by detecting the absorbance using a microplate reader at a wavelength of 570 nm (BioTek Synergy, Analytical and Diagnostic Products, Johannesburg, South Africa). The wells in column 1 and 12, containing medium and MTT but no cells was used to blank the microplate reader. The percentage of cell viability was calculated using the formula below:

$$\%\text{Cell}\hspace{0.17em}\text{viability}\hspace{0.17em}=\hspace{0.17em}\frac{\text{Mean}\hspace{0.17em}\text{Absorbance}\hspace{0.17em}\hspace{0.17em}\text{of}\hspace{0.17em}\text{sample}\hspace{0.17em}\times \hspace{0.17em}100}{\text{Mean}\hspace{0.17em}\text{Absorbance}\hspace{0.17em}\text{of}\hspace{0.17em}\text{control}}$$

The LC₅₀ values (lethal concentration at which 50% of the cells are killed) were calculated as the concentration of the test sample that resulted in 50% reduction of absorbance compared to untreated cells. The intensity of the MTT formazan produced by living metabolically active cells is directly proportional to the number of live cells present.

3.8. Methodology-Docking Simulation

3.8.1. Protein Structure

The starting structure of parasite lactate dehydrogenase (pLDH) was obtained from PDB (PDB id: 1T24) with 1.7 Å resolution. All heteroatoms and water molecules were removed pLDH. Polar hydrogen atoms, Kollman-Amber united atom partial charges and solvation parameters were added by utilizing AutoDockTools [29].

3.8.2. Ligand Structure

The initial structure of positive control 4-hydroxy-1,2,5-oxazole-3-carboxylic acid (OXD) was obtained from the ligand of pLDH (PDB id: 1T24) while the coordinates for test compound 3a, 3f, 4a and 4g were generated using Hyperchem 7.0 (Hypercube Inc., Gainesville, FL, USA). All ligands were retained with polar hydrogen atoms. Gasteiger charges and torsional angles were added by utilizing AutoDockTools [29].

3.8.3. Molecular Docking Simulation

Grid maps of 40 × 40 × 40 points with 0.375 Å spacing were centered at OXD binding site in the crystal structure (PDB id: 1T24) for positive control docking and the docking of lactate (the substrate of pLDH). While for compound 3(a,f) and 4(a,g), the grid maps of 50 × 50 × 50 points with 0.375 Å spacing were centered at NAD+ of the crystal structure (PDB id: 1T24). A total of 200 docking runs by AutoDock4.2.6 [30] were performed by employing Lamarckian genetic algorithm with 2,500,000 energy evaluations per run and maximum number of 27,000 generation. The number of individuals in population was 150 and the crossover rate was 0.8. The results were processed by conformational cluster analysis with 1.0 Å cut-off for positive control and 2.0 Å cut-off for lactate, 3(a,f) and 4(a,g). The ligand conformation with lowest free energy of binding in the most populated cluster was selected for comparison.

4. Conclusions

The oximes derived from the 1-(2,5-diarylindol-7-yl)ethanones undergo sequential or direct one-pot successive TFA-mediated Beckmann rearrangement followed by trifluoroacetylation of the intermediate N-(2,5-diarylindol-7-yl)acetamides with TFAA to afford the C-3 trifluoroacetylated derivatives, exclusively. The preliminary in vitro antiplasmodial activity results against the chloroquine-sensitive strain of malaria parasite for both N-(2,5-diarylindol-7-yl)acetamides and their 3-trifluoroacetyl–substituted derivatives reveal that the entire 7-aminoindole framework is required for biological activity. Structure-activity relationship and molecular docking indicate that the optimal aryl substituent at the 5-position of the indole derivatives 3 and 4 is the 4-fluorophenyl or 4-fluorostyryl group. Molecular docking of the most active compounds 3a, 3f, 4a and 4g against the parasite lactate dehydrogenase (pLDH) reveal that the indole derivatives prepared in this investigation presumably act through different mechanism of action to that of chloroquine. They will probably not compete with lactate for its binding site, but might block the entrance of lactate to cause the observed inhibition effects. Future studies should involve an enzyme inhibition assay against lactate dehydrogenase activity to measure parasite viability. Despite the fact that the IC₅₀ values of these compounds (1400–14,000 nM) fall much short of the nanomolar activity of chloroquine (10 nM), these preliminary antiplasmodial activity results suggest that the indole derivatives are worthy of further studies to develop new drugs with novel mechanisms of action and reduced toxicity.